Tag: Dr Stephen Tilles
Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...
73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.
Aimmune Presents New Clinical Data From Patients Treated With PALFORZIA® for...
Majority of patients experienced low rates of adverse events which declined in frequency and severity with continued treatment.
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.
New Treatment to Protect People with Peanut Allergies Ready for FDA...
"Two thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after 9 to 12 months of treatment."
